Other research analysts also recently issued research reports about the stock. HC Wainwright started coverage on shares of Calithera Biosciences in a report on Wednesday, November 27th. They set a buy rating and a $7.00 price objective on the stock. Zacks Investment Research upgraded shares of Calithera Biosciences from a sell rating to a hold rating in a report on Monday, November 18th. Finally, Citigroup set a $8.00 price objective on shares of Calithera Biosciences and gave the company a hold rating in a report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $6.50.
Shares of NASDAQ:CALA opened at $4.68 on Wednesday. Calithera Biosciences has a twelve month low of $2.45 and a twelve month high of $6.90. The stock’s 50 day moving average is $3.58 and its 200-day moving average is $4.02. The company has a quick ratio of 7.39, a current ratio of 7.39 and a debt-to-equity ratio of 0.06.
In other news, major shareholder Bvf Partners L. P/Il acquired 191,954 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were purchased at an average cost of $3.91 per share, with a total value of $750,540.14. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Value Fund L. P. Biotechnology acquired 88,253 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were purchased at an average cost of $4.30 per share, for a total transaction of $379,487.90. Insiders have acquired a total of 4,404,157 shares of company stock valued at $13,700,668 over the last three months. Corporate insiders own 17.20% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of CALA. Beddow Capital Management Inc. bought a new position in shares of Calithera Biosciences during the second quarter valued at about $44,000. Wedbush Securities Inc. bought a new stake in Calithera Biosciences in the 3rd quarter worth about $42,000. Tower Research Capital LLC TRC purchased a new stake in Calithera Biosciences in the 2nd quarter valued at about $56,000. Panagora Asset Management Inc. purchased a new stake in Calithera Biosciences in the 2nd quarter valued at about $60,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Calithera Biosciences in the 2nd quarter valued at about $63,000. Hedge funds and other institutional investors own 65.82% of the company’s stock.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Featured Article: Neutral Rating
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.